Leap Therapeutics (FRA:5MC) Total Tax Payable : €0.51 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics Total Tax Payable?

Leap Therapeutics's Total Tax Payable for the quarter that ended in Dec. 2024 was €0.51 Mil.

Leap Therapeutics's quarterly Total Tax Payable increased from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€0.65 Mil) but then declined from Sep. 2024 (€0.65 Mil) to Dec. 2024 (€0.51 Mil).

Leap Therapeutics's annual Total Tax Payable stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.51 Mil).

Leap Therapeutics Total Tax Payable Historical Data

The historical data trend for Leap Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Total Tax Payable Chart

Leap Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Tax Payable

Get a 7-Day Free Trial

0.51

Leap Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Tax Payable	Get a 7-Day Free Trial															-	-	-	0.65	0.51

Leap Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Leap Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

LPTX:USA 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

Leap Therapeutics Headlines

No Headlines